Background To prevent the development of drug resistance, the World Health Organization
(WHO) recommends treating malaria with combination therapy. Azithromycin, an antibiotic …

Plasmodium vivax is the most prevalent malaria infection and is an important cause of
morbidity in Central and South America and Asia. P. vivax is generally sensitive to the …

The gametocytocidal and asexual stage activities of eight antimalarial and eight antibiotic-
containing regimens were evaluated in 349 adult patients with P. vivax malaria …

Etwa 40% der Weltbevölkerung leben in Malariagebieten. Jährlich erkranken 300 bis 500
Millionen Menschen an Malaria, bis zu 2.5 Millionen sterben an den Krankheitsfolgen …

Human diseases like malaria, toxoplasmosis or cryptosporidiosis are caused by intracellular
protozoan parasites of the phylum Apicomplexa and are still a major health problem …

Lincomycin and clindamycin are the only members of the relatively small lincosamide
antimicrobial class marketed for use in humans. This paper only reviews data regarding …

Azithromycin has demonstrated activity in a prevention of Plasmodium vivax infection, but no
controlled treatment studies have been performed. We conducted a double-blinded trial in P …

We assessed the prophylactic efficacy of azithromycin (250 mg/day) against malaria in 276
adults in western Thailand in a randomized, double-blind, placebo-controlled trial. After …

Mixed Plasmodium malariae and P. vivax infections in humans are reported very
infrequently. The case of a 27-year-old male who sustained malaria quartana/tertiana …

The mitochondrial rRNA of the tapeworm species Echinococcus multilocularis carries an
adenine at sequence position 2058 (numbering according to that for Escherichia coli) of the …